CN103948930B - A kind of poultry compound medicine containing Radix Paeoniae Rubra and beta-lactam antimicrobial drug - Google Patents
A kind of poultry compound medicine containing Radix Paeoniae Rubra and beta-lactam antimicrobial drug Download PDFInfo
- Publication number
- CN103948930B CN103948930B CN201410202810.5A CN201410202810A CN103948930B CN 103948930 B CN103948930 B CN 103948930B CN 201410202810 A CN201410202810 A CN 201410202810A CN 103948930 B CN103948930 B CN 103948930B
- Authority
- CN
- China
- Prior art keywords
- radix paeoniae
- drug
- paeoniae rubra
- antimicrobial drug
- beta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 65
- 239000004599 antimicrobial Substances 0.000 title claims abstract description 39
- 150000001875 compounds Chemical class 0.000 title claims abstract description 26
- 150000003952 β-lactams Chemical class 0.000 title claims abstract description 17
- 244000144977 poultry Species 0.000 title claims abstract description 15
- 229940079593 drug Drugs 0.000 claims abstract description 28
- 239000000843 powder Substances 0.000 claims abstract description 15
- 229960003022 amoxicillin Drugs 0.000 claims abstract description 11
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims abstract description 11
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims abstract description 11
- RFLHUYUQCKHUKS-JUODUXDSSA-M Ceftiofur sodium Chemical compound [Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC(=O)C1=CC=CO1 RFLHUYUQCKHUKS-JUODUXDSSA-M 0.000 claims abstract description 9
- 229960004467 ceftiofur sodium Drugs 0.000 claims abstract description 9
- 239000008187 granular material Substances 0.000 claims abstract description 7
- 239000007788 liquid Substances 0.000 claims abstract description 7
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims description 3
- 101100346764 Mus musculus Mtln gene Proteins 0.000 claims 1
- GFRSPXVZLZZNMD-UHFFFAOYSA-N [Na].O1C=CC=C1.S1C=CC=C1 Chemical compound [Na].O1C=CC=C1.S1C=CC=C1 GFRSPXVZLZZNMD-UHFFFAOYSA-N 0.000 claims 1
- 206010059866 Drug resistance Diseases 0.000 abstract description 28
- 230000001580 bacterial effect Effects 0.000 abstract description 5
- 235000013305 food Nutrition 0.000 abstract description 5
- 241001465754 Metazoa Species 0.000 abstract description 4
- 238000007796 conventional method Methods 0.000 abstract description 4
- 239000003640 drug residue Substances 0.000 abstract description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 230000002441 reversible effect Effects 0.000 abstract description 3
- 229960000479 ceftriaxone sodium Drugs 0.000 abstract description 2
- FDRNWTJTHBSPMW-GNXCPKRQSA-L disodium;(6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-6-oxido-5-oxo-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound [Na+].[Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)/C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C([O-])=NN1C FDRNWTJTHBSPMW-GNXCPKRQSA-L 0.000 abstract description 2
- 241000287828 Gallus gallus Species 0.000 description 38
- 235000013330 chicken meat Nutrition 0.000 description 37
- 241000607142 Salmonella Species 0.000 description 22
- 241000588724 Escherichia coli Species 0.000 description 18
- 241000272525 Anas platyrhynchos Species 0.000 description 17
- 230000000694 effects Effects 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 230000000844 anti-bacterial effect Effects 0.000 description 10
- 235000013594 poultry meat Nutrition 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 206010039438 Salmonella Infections Diseases 0.000 description 7
- 206010039447 salmonellosis Diseases 0.000 description 7
- 229940126575 aminoglycoside Drugs 0.000 description 6
- 210000003608 fece Anatomy 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000011285 therapeutic regimen Methods 0.000 description 6
- 241000271566 Aves Species 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 244000052616 bacterial pathogen Species 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 108090000204 Dipeptidase 1 Proteins 0.000 description 3
- 208000037386 Typhoid Diseases 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 102000006635 beta-lactamase Human genes 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 201000008297 typhoid fever Diseases 0.000 description 3
- 241000272522 Anas Species 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 206010061126 Escherichia infection Diseases 0.000 description 2
- 108010062679 Gentamicin 2''-nucleotidyltransferase Proteins 0.000 description 2
- 206010019842 Hepatomegaly Diseases 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 238000010876 biochemical test Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 208000020612 escherichia coli infection Diseases 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 229960000308 fosfomycin Drugs 0.000 description 2
- YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 2
- 230000012447 hatching Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000003771 laboratory diagnosis Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- FKENQMMABCRJMK-RITPCOANSA-N sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 description 2
- 229960005256 sulbactam Drugs 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- NDIURPSCHWTXDC-UHFFFAOYSA-N 2-(4,5-dimethoxy-2-nitrophenyl)acetohydrazide Chemical compound COC1=CC(CC(=O)NN)=C([N+]([O-])=O)C=C1OC NDIURPSCHWTXDC-UHFFFAOYSA-N 0.000 description 1
- 108700016155 Acyl transferases Proteins 0.000 description 1
- 102000057234 Acyl transferases Human genes 0.000 description 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N Calcium oxide Chemical compound [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 108090000119 Nucleotidyltransferases Proteins 0.000 description 1
- 102000003832 Nucleotidyltransferases Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000027954 Poultry disease Diseases 0.000 description 1
- 241000607132 Salmonella enterica subsp. enterica serovar Gallinarum Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 229960000510 ammonia Drugs 0.000 description 1
- 229940038195 amoxicillin / clavulanate Drugs 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- 229960003644 aztreonam Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229940041011 carbapenems Drugs 0.000 description 1
- 229960005229 ceftiofur Drugs 0.000 description 1
- ZBHXIWJRIFEVQY-IHMPYVIRSA-N ceftiofur Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC(=O)C1=CC=CO1 ZBHXIWJRIFEVQY-IHMPYVIRSA-N 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 244000144992 flock Species 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000005571 horizontal transmission Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 229960000373 tazobactam sodium Drugs 0.000 description 1
- 229940041007 third-generation cephalosporins Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000005570 vertical transmission Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Fodder In General (AREA)
Abstract
The present invention relates to a kind of containing Radix Paeoniae Rubra with the poultry compound medicine of beta-lactam class antimicrobial drug, be made up of the raw material of following weight portion: beta-lactam class antimicrobial drug 3 30 parts, Radix Paeoniae Rubra 5 200 parts；Described beta-lactam class antimicrobial drug is amoxicillin, ceftriaxone sodium or ceftiofur sodium.The present invention can the reverse bacterial drug resistance to antimicrobial drug, thus improve the therapeutic effect of antimicrobial drug.According to a conventional method this compound medicine is made powder, tablet, oral liquid or granule, add in animal and fowl fodder according to the addition of 0.1 7g principal agent/kg feedstuff and feed, drug cost and drug residue can be greatly reduced, create higher economic benefit for raiser, also ensure that food safety simultaneously.
Description
Technical field
The invention belongs to poultry escherichia coli and Salmonella infection treatment technology field, particularly relate to a kind of containing Radix Paeoniae Rubra
Poultry compound medicine with beta-lactam antimicrobial drug.
Background technology
Fowl salmonellosis (Avian salmonellosis) is by one or more Salmonellas in Salmonella
The general name of caused poultry disease.Difference according to pathogen antigen structure can be divided into 3 classes: Pullorum Disease, avian typhoid and fowl are secondary
Typhoid fever.Wherein Pullorum Disease and avian typhoid Salmonella have host specificity, mainly cause chicken and turkey morbidity；And avian paratyphoid is husky
Door Salmonella then can extensively infect many animals and people, is mankind's Salmonella infection and food by its poultry polluted and products thereof
One of main source of poisoning.Fowl salmonellosis is commonly formed considerably complicated propagation circulation.Sick fowl and the fowl that carries disease germs are main
The source of infection, can pass through digestive tract, respiratory tract or eye conjunctiva horizontal transmission, can infect poult, cause big portion after ovum vertical transmission
Dividing death, poultry carries disease germs for a long time, the ovum that then output is carried disease germs, if hatching in this, as hatching egg, then and the generation can gone round and begun again
In generation, passes on from one to another, and causes fowl salmonellosis to be difficult to purify in chicken group, causes serious economic loss.Owing to Salmonella is chicken group
Middle pollution face is big, and is easily generated drug resistance, and immune effect of vaccine in the market is the most undesirable.Therefore, breeder flock quarantine, medicine
Thing controls, environment disinfected purifies, strengthen feeding and management and health and epidemic prevention is still and controls and prevent Salmonella from entering food chain
Essential measure.Chickling is drunk 0.01% potassium permanganate solution or other drug 1～carries out chemoprophylaxis in 2 days after going out shell.This bacterium pair
Common drug produces drug resistance, forces and has to carry out various medicine in production and be used alternatingly, in the hope of preferably controlling fastbacteria.
This bacterium produces stronger drug resistance to aminoglycoside medicaments at present, and aminoglycoside inactive enzyme is to these antibacterials molecules
In some protection antibacterial activity necessary to group modify so that it is affinity ribosomal with target site is greatly lowered.
These inactive enzymes include aminoglycoside acyltransferase (AAC), aminoglycoside adenylyl transferase (AAD), aminoglycoside phosphorus
Acid transferring enzyme (APH), gland nucleotidyltransferase (ANT) etc..The most it is found that not in the fastbacteria of many aminoglycosides
Inactive enzyme with characteristic.
Escherichia coli are common conditioned pathogens, are also a kind of diseases often sent out, and it primary can cause the acute deteriorated blood of chicken
The multiple location severe infections such as disease, peritonitis, hepatitis, pneumonia, enteritis, also can secondary or mixed send out in virosis, cause to aquaculture
Huge economic loss.Amoxicillin, ampicillin, ceftiofur, ceftriaxone, amoxicillin/clavulanate, ammonia benzyl west
The beta-lactam nucleus class antibiotic such as woods/sulbactam are the conventional important drugs preventing and treating this disease, along with the cultivation intensive journey of scale
Degree is more and more big, and medication is more and more spread unchecked, and its Resistant strain is the most, and the report about Drug Resistance of E. coli is the most more.
Research confirms, one of main mechanism of drug resistance is to produce beta-lactamase, especially extended spectrumβ-lactamase (Extended-
Spectrum β-lactamase, ESBLs), this enzyme can hydrolyze beta-lactam nucleus more by force and rapidly, makes this kind of antibiotic lose
Antibacterial activity.ESBLs is the main enzyme type of beta-lactamase, and it is not only to cephalo three generations and aztreonam drug resistance, and to ammonia
Base glucosides class, quinolones and sulfonamides are crossing drug resistant, only to carbapenems, a mould alkenes medicaments insensitive.Many documents
It has been reported that colibacillary multi-drug resistant with produce ESBLs have substantial connection, both at home and abroad to more pay close attention to.Inventor is
The detection of food animal source pathogenic bacterium ESBLs, extraction, enzyme are closely carried out to the percent hydrolysis of antibiotic and sulbactam, Tazobactam Sodium
And the research such as the enzyme protection effect that presses down of Chinese medicine, drug sensitive test colibacillary to part ESBLs shows, its multidrug resistant rate is bright
Aobvious higher than non-ESBLs bacterial strain.It addition, result also shows that product ESBLs bacterial strain is not only tight to third generation cephalosporins such as ceftiofurs
Weight drug resistance, and also antimicrobial drug drug resistance multiple to fluoroquinolones, aminoglycoside and sulfonamides, fosfomycin etc., in serious
Multidrug resistant.Inventor is separated to resistance to fosfomycin in producing ESBLs bacterial strain and produces the escherichia coli of fosA3 drug resistant gene, more strengthens
The drug resistance of antibacterial.
Salmonella and colibacillary drug resistance cause raiser's drug cost to increase, and treatment extends the course for the treatment of, and poultry are dead
Rate of dying increases, and brings bigger economic loss to production, and increases poultry drug residue risk.Therefore, actual production is needed badly
A kind of to regardless of whether the Salmonella of drug resistance and escherichia coli can have a medicine of preferable therapeutical effect, and treatment can be shortened treat
Journey, reduces mortality rate, reduces economic loss and reduces drug residue, creating higher economic benefit for raiser, also ensure people
Class healthy and safe.
Summary of the invention
The technical problem to be solved in the present invention is to provide a kind of poultry containing Radix Paeoniae Rubra and beta-lactam antimicrobial drug with multiple
Side's medicine, it can kill antibacterial quickly, overcome weak curative effect that antimicrobial drug treatment causes due to drug resistance problems, consumption big,
The defect that residual is high and cost is high, it is to avoid simple Chinese medicine sterilizing spectrum is narrow, sterilize slow problem.
For solving above technical problem, the present invention by the following technical solutions: a kind of resist containing Radix Paeoniae Rubra and beta-lactam
The poultry compound medicine of bacterium medicine, is made up of the raw material of following weight portion: beta-lactam antimicrobial drug 3-30 part, Radix Paeoniae Rubra 5-200
Part.
Described beta-lactam antimicrobial drug is amoxicillin, ceftriaxone sodium or ceftiofur sodium.
Further, described compound medicine is made up of the raw material of following weight portion: amoxicillin 3-20 part and Radix Paeoniae Rubra 40-
180 parts, or ceftiofur sodium 3-25 part and Radix Paeoniae Rubra 30-190 part.
Described compound medicine is prepared as powder, tablet, oral liquid or granule.
The preparation method of described compound medicine is: Radix Paeoniae Rubra pulverized 60 mesh sieves, then mixes with the antimicrobial drug of powder,
It is prepared as powder, tablet, oral liquid or granule according to a conventional method.
The drug resistance problems existed for current poultry escherichia coli and Salmonella infection, inventor utilizes Lactiflora
Compound medicine is formed with antimicrobial drug.Research proves, after adding Radix Paeoniae Rubra in antimicrobial drug, it is possible to the reverse bacterial drug resistance to antimicrobial drug
Property, thus improve the therapeutic effect of antimicrobial drug.According to a conventional method this compound medicine is made powder, tablet, oral liquid or granule
Agent, adds in animal and fowl fodder according to the addition of 0.1-7g principal agent/kg feedstuff and feeds, can be greatly reduced drug cost and
Drug residue, creates higher economic benefit for raiser, also ensure that food safety simultaneously.
Detailed description of the invention
One, the Radix Paeoniae Rubra drug resistance inversion Effect study to antimicrobial drug
Antimicrobial drug itself has treatment escherichia coli and the effect of Salmonella, but owing to producing the escherichia coli of drug resistant gene
With Salmonella, there is stronger drug resistance, cause antimicrobial drug not show in the case of normal using dosage and preferably control
Therapeutic effect.
1, to colibacillary drug resistance inhibition test after Radix Paeoniae Rubra mixes with antimicrobial drug
96 orifice plates use microtest tube doubling dilution, first determines antimicrobial drug to producing ESBLs and fosA3 drug resistance base
Minimal inhibitory concentration and the Radix Paeoniae Rubra of the e. coli strains of cause are antibacterial to the Asia producing ESBLs and fosA3 drug resistant gene e. coli strains
Concentration, add the most in the medium the Radix Paeoniae Rubra of subinhibitory concentration reuse microtest tube doubling dilution cultivate measure antibacterial
The minimal inhibitory concentration of medicine；Utilize continuous passage method added with same subinhibitory concentration Radix Paeoniae Rubra and the cultivation of same concentration antimicrobial drug
Base carries out Secondary Culture, until the antimicrobial drug minimum observed is antibacterial to product ESBLs and fosA3 drug resistant gene e. coli strains
Concentration with pass on before compared with diminish more than 4 times, can be judged as that Radix Paeoniae Rubra has drug resistance inversion effect to antibacterial medical instrument.Result of the test is united
Meter is as shown in table 1:
Table 1 subinhibitory concentration (0.5g/mL) Radix Paeoniae Rubra passes on and causes the change producing ESBLs and fosA3 escherichia coli Western medicine MIC
(μg/mL)。
As seen from the above table, antimicrobial drug all reduces more than 4 times to the minimal inhibitory concentration of antibiotic-resistance E. coli, i.e. can determine whether be
Radix Paeoniae Rubra has drug resistance inversion effect to producing ESBLs and fosA3 drug resistant gene escherichia coli.
2, drug resistance inhibition test to Salmonella after Radix Paeoniae Rubra mixes with antimicrobial drug
96 orifice plates use microtest tube doubling dilution, first determines the antimicrobial drug minimum to drug resistance salmonella strain
Mlc and the Radix Paeoniae Rubra subinhibitory concentration to drug resistance salmonella strain, add the Radix Paeoniae Rubra of subinhibitory concentration the most in the medium
Reuse microtest tube doubling dilution and cultivate the minimal inhibitory concentration measuring antimicrobial drug；Utilize continuous passage method added with same
The culture medium of sample subinhibitory concentration Radix Paeoniae Rubra and same concentration antimicrobial drug carries out Secondary Culture to Salmonella persister, until seeing
The antimicrobial drug minimal inhibitory concentration measured with pass on before compared with diminish more than 4 times, can be judged as that antibacterial medical instrument is had resistance to by Radix Paeoniae Rubra
Medicine reverse effect.Result of the test statistics is as shown in table 2:
Table 2 subinhibitory concentration (0.5g/mL) Radix Paeoniae Rubra passes on the change (μ g/mL) causing drug resistance Salmonella Western medicine MIC.
As seen from the above table, antimicrobial drug all reduces more than 4 times to the minimal inhibitory concentration of drug resistance Salmonella, i.e. can determine whether be
Radix Paeoniae Rubra has drug resistance inversion effect to drug resistance Salmonella.
Two, the application example of compound medicine of the present invention
Embodiment 1-embodiment 8 is prepared: after Radix Paeoniae Rubra was pulverized 60 mesh sieves, as base according to table 3 formula and following methods
Plinth raw material, then mix, according to a conventional method, by compound medicine system during ratio puts into blender by weight with the antimicrobial drug of powder
Standby one-tenth formulation products.
The formula of table 3 embodiment 1-8 and preparation dosage form
| Numbering | Antimicrobial drug | Radix Paeoniae Rubra | Dosage form |
| Embodiment 1 | Amoxicillin 3g | 120g | Tablet |
| Embodiment 2 | Amoxicillin 10g | 90g | Powder |
| Embodiment 3 | Amoxicillin 14g | 40g | Oral liquid |
| Embodiment 4 | Amoxicillin 20g | 180g | Granule |
| Embodiment 5 | Ceftiofur sodium 13g | 190g | Tablet |
| Embodiment 6 | Ceftiofur sodium 15g | 85g | Powder |
| Embodiment 7 | Ceftiofur sodium 3g | 5g | Oral liquid |
| Embodiment 8 | Ceftiofur sodium 25g | 30g | Granule |
Above-described embodiment is obtained compound medicine product and has carried out following experiment by inventor:
1, the compound medicine product of the embodiment 1-4 gained efficacy experiment to chicken escherichia coil disease
Clinical symptoms: Guigang, Guangxi chicken house, 25 Day-old Broiler Chickens, there is fragmentary death in chicken group, cuts open the indivedual chickens of inspection and bag occurs
Pericardium liver pathological change, typical bacillus coli feature.
Laboratory diagnosis: take pathologic liver dye sheet, Gram’s staining, basis of microscopic observation, it is seen that red gram-negative
Property bacillus；Tentatively it is judged as bacillus coli.Being cultivated by escherichia coli, biochemical test differentiates, it is judged that it is big that chicken infects
Enterobacteria disease, PCR expands, it was demonstrated that produce the ESBLs drug resistant gene having TEM type.
Test therapeutic regimen: morbidity chicken group is divided into 6 groups of administrations, first group by embodiment 1 according to the interpolation of 7g/kg feedstuff
Amount is administered, and second group is administered according to the addition of 2g/kg feedstuff by embodiment 2, raises according to 0.8g/kg by embodiment 3 for the 3rd group
The addition of material is administered, and the 4th group is administered according to the addition of 2g/kg feedstuff by embodiment 4；Use amoxicillin powder for 5th group
Being administered according to the addition of 0.2g/kg feedstuff, the 6th group is administered according to the addition of 4g/kg feedstuff with the thick powder of Radix Paeoniae Rubra；Above
Six groups of therapeutic regimens the most persistently use 5 days.
Staining effect: after chicken group's medication of first group to the 4th group, sick chicken feed intake rises, and dead chicken no longer occurs, continues
Using 3 days, chicken group be almost recovered；After chicken group's medication of the 5th group 2 days, chicken group's majority is the most unhealthy, still has indivedual chicken death, continues
Continuous use 3 days, chicken death phenomenon is still without being effectively controlled；After chicken group's medication of the 6th group 2 days, the not biggest bright of chicken group
Aobvious change, is continuing with 3 days, and chicken death phenomenon is still without being effectively controlled.Visible, the compound medicine curative effect containing Radix Paeoniae Rubra is excellent
In folk prescription.
2, the efficacy experiment that the meat-type duck of 20 ages in days is suffered from diarrhoea by the compound medicine product of embodiment 5-8 gained
Clinical symptoms: duck field, Nanning, 20 age in days meat-type duck, duck group draws watery stools, has and significantly do not disappear in feces
The feedstuff changed.Duck group material feeding but the longest, indivedual serious ducks of suffering from diarrhoea gradually occur that foot is soft slowly dead.
Cuing open inspection pathological changes: the duck that dies of illness dehydration ratio is more serious, indivedual ducks are the biggest, duck liver enlargement, hyperemia, the liver of part duck
Having white films on dirty, air bag is muddy, and tentative diagnosis is escherichia coli or duck oromeningitis.
Test therapeutic regimen: morbidity duck group divides six groups of administrations, first group by embodiment 5 according to the addition of 3g/kg feedstuff
Being administered, second group is administered according to the addition of 1.3g/kg feedstuff by embodiment 6, raises according to 0.5g/kg by embodiment 7 for the 3rd group
The addition of material is administered, and the 4th group is administered according to the addition of 0.45g/kg feedstuff by embodiment 8；Use ceftiofur sodium for 5th group
Powder is administered according to the addition of 0.2g/kg feedstuff, and the 6th group is administered according to the addition of 5g/kg feedstuff with the thick powder of Radix Paeoniae Rubra；
Above six groups of therapeutic regimens the most persistently use 5 days.
Using effect is fed back: after first group to the 4th group medication 2 days, and sick duck no longer draws watery stools, formed stools, no longer
Dead duck occur, be continuing with 3 days, duck group be almost recovered；After 5th group of medication 2 days, duck group's DeGrain, the most still draws water
Sample feces, containing indigested feedstuff, is continuing with 3 days, somewhat takes a turn for the better, but the best thorough, and dilute watery stools is still
Occurring, using the compound medicine of embodiment 6 gained instead, be continuing with 2 days, be just almost recovered, re-use 1 day, feces all transfers to
Normally；After 6th group of medication 2 days, duck does not has the biggest remarkable improvement, is continuing with 3 days, and the duck phenomena of mortality are still without being had
Effect controls.Visible, the curative effect that duck is suffered from diarrhoea by compound medicine containing Radix Paeoniae Rubra is better than folk prescription.
3, embodiment 1-4 obtains the compound medicine product efficacy experiment to Salmonella gallinarum disease
Clinical symptoms: Liuzhou chicken house, 13 age in days laying hens, there is dysentery, row's white, pasty state loose stool, anus in chicken group
Tomentum fecal pollution around, has Calx sample lump, the shriek sending misery having, and has the phenomena of mortality.Cut open the indivedual chickens of inspection
Hepatomegaly be kermesinus to darkviolet, or slightly khaki, matter is crisp fragile, and surface is dispersed in or gathers greyish white, the downright bad point of lark,
Sometimes it is red petechia, typical Salmonella genius morbi.
Laboratory diagnosis: take pathologic liver dye sheet, Gram’s staining, basis of microscopic observation, it is seen that red gram-negative
Property bacillus；Tentatively it is judged as Salmonella disease.Being cultivated by Salmonella, biochemical test differentiates, it is judged that chicken infects for sand
Door Salmonella disease, drug sensitive test result is judged as persister Salmonella according to NCCLS standard.
Test therapeutic regimen: morbidity chicken group is divided into 6 groups of administrations, first group by embodiment 1 according to the interpolation of 7g/kg feedstuff
Amount is administered, and second group is administered according to the addition of 2g/kg feedstuff by embodiment 2, raises according to 0.8g/kg by embodiment 3 for the 3rd group
The addition of material is administered, and the 4th group is administered according to the addition of 2g/kg feedstuff by embodiment 4；Use amoxicillin powder for 5th group
Being administered according to the addition of 0.2g/kg feedstuff, the 6th group is administered according to the addition of 4g/kg feedstuff with the thick powder of Radix Paeoniae Rubra；Above
Six groups of therapeutic regimens the most persistently use 5 days.
Staining effect: after chicken group's medication of first group to the 4th group, sick chicken feed intake rises, and dead chicken no longer occurs, continues
Using 3 days, chicken group be almost recovered；After chicken group's medication of the 5th group 2 days, chicken group's majority is the most unhealthy, still has indivedual chicken death, continues
Continuous use 3 days, chicken death phenomenon is still without being effectively controlled；After chicken group's medication of the 6th group 2 days, the not biggest bright of chicken group
Aobvious change, is continuing with 3 days, and chicken death phenomenon is still without being effectively controlled.Visible, the compound medicine curative effect containing Radix Paeoniae Rubra is excellent
In folk prescription.
Claims (3)
1. one kind contains Radix Paeoniae Rubra and the poultry compound medicine of beta-lactam antimicrobial drug, it is characterised in that by following weight portion
Raw material composition: beta-lactam antimicrobial drug 3-30 part, Radix Paeoniae Rubra 5-200 part；Described beta-lactam antimicrobial drug is A Moxi
Woods or ceftiofur sodium.
Poultry compound medicine containing Radix Paeoniae Rubra and beta-lactam antimicrobial drug the most according to claim 1, its feature exists
In, described compound medicine is made up of the raw material of following weight portion: amoxicillin 3-20 part and Radix Paeoniae Rubra 40-180 part, or cephalo thiophene
Furan sodium 3-25 part and Radix Paeoniae Rubra 30-190 part.
3. according to the poultry compound medicines containing Radix Paeoniae Rubra and beta-lactam antimicrobial drug according to any one of claim 1-2
Thing, it is characterised in that described compound medicine is prepared as powder, tablet, oral liquid or granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410202810.5A CN103948930B (en) | 2014-05-14 | 2014-05-14 | A kind of poultry compound medicine containing Radix Paeoniae Rubra and beta-lactam antimicrobial drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410202810.5A CN103948930B (en) | 2014-05-14 | 2014-05-14 | A kind of poultry compound medicine containing Radix Paeoniae Rubra and beta-lactam antimicrobial drug |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103948930A CN103948930A (en) | 2014-07-30 |
| CN103948930B true CN103948930B (en) | 2016-08-31 |
Family
ID=51326368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410202810.5A Expired - Fee Related CN103948930B (en) | 2014-05-14 | 2014-05-14 | A kind of poultry compound medicine containing Radix Paeoniae Rubra and beta-lactam antimicrobial drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103948930B (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104306881A (en) * | 2014-10-10 | 2015-01-28 | 天津瑞贝特科技发展有限公司 | Injection for preventing and treating poultry escherichia coli diseases and preparation method of injection |
| CN104306422A (en) * | 2014-11-07 | 2015-01-28 | 广西大学 | Balsamiferou Blumea herb and beta-lactam antibacterial drug containing compound medicine for livestock and poultry |
| CN104435011A (en) * | 2014-11-12 | 2015-03-25 | 广西大学 | Compound medicine containing herba pteridis multifidae and beta-lactam antibiotics drugs for livestock and poultry |
| CN105726588A (en) * | 2016-01-29 | 2016-07-06 | 广西大学 | Compound medicine containing radix helicteris and sulfamonomethoxine sodium for livestock and poultry |
| CN106265880A (en) * | 2016-08-22 | 2017-01-04 | 广西大学 | A kind of poultry compound medicine containing Radix Glycyrrhizae and ceftiofur sodium |
| CN106214742A (en) * | 2016-08-22 | 2016-12-14 | 广西大学 | A kind of poultry compound medicine containing Cortex Cinnamomi and ceftiofur sodium |
| CN106138184A (en) * | 2016-08-22 | 2016-11-23 | 广西大学 | A kind of poultry compound medicine containing Radix Glycyrrhizae and amoxicillin |
| CN106176895A (en) * | 2016-08-22 | 2016-12-07 | 广西大学 | A kind of poultry compound medicine containing Herba Euphorbiae Humifusae and amoxicillin |
| CN106421791A (en) * | 2016-08-29 | 2017-02-22 | 广西大学 | Compound pharmaceutical product containing desmodium triquetrum and beta-lactam antibiotics drugs for beasts and birds |
| CN106309555A (en) * | 2016-09-21 | 2017-01-11 | 广西大学 | Composite medicine containing liquorice roots, cinnamon and ceftiofur sodium for beasts and birds |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003238430A (en) * | 2002-02-13 | 2003-08-27 | Hajime Ikegai | Antibacterial extract, method for producing the same and antibacterial agent composition |
| CN103212079A (en) * | 2013-04-26 | 2013-07-24 | 陆媛 | Oral medical composition for preventing and/or treating cold and application thereof |
| CN104688995A (en) * | 2015-01-27 | 2015-06-10 | 青岛市市立医院 | Medicine for treatment of condyloma acuminate and preparation method thereof |
-
2014
- 2014-05-14 CN CN201410202810.5A patent/CN103948930B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003238430A (en) * | 2002-02-13 | 2003-08-27 | Hajime Ikegai | Antibacterial extract, method for producing the same and antibacterial agent composition |
| CN103212079A (en) * | 2013-04-26 | 2013-07-24 | 陆媛 | Oral medical composition for preventing and/or treating cold and application thereof |
| CN104688995A (en) * | 2015-01-27 | 2015-06-10 | 青岛市市立医院 | Medicine for treatment of condyloma acuminate and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 中西药的合理配伍应用;吴淑站;《现代中西医结合杂志》;20080430;第17卷(第10期);第1552-1553页，尤其第1552页右栏第9-12行 * |
| 赤芍提取物体外抑菌活性的研究;张芳等;《徐州医学院学报》;20061231;第26卷(第5期);第418-420页，尤其摘要 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103948930A (en) | 2014-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103948930B (en) | A kind of poultry compound medicine containing Radix Paeoniae Rubra and beta-lactam antimicrobial drug | |
| CN103989728B (en) | It is a kind of to contain the livestock and poultry compound medicine containing pearl grass and beta-lactam class antimicrobial | |
| CN103977090B (en) | A kind of poultry compound medicine containing Radix Paeoniae Rubra and florfenicol | |
| CN103690952B (en) | The compound medicine for the treatment of poultry coli-infection disease | |
| CN103977089B (en) | A kind of poultry compound medicine containing Radix Paeoniae Rubra and fosfomycin | |
| CN103961421A (en) | Compound medicine containing radix paeoniae rubra and mequindox for livestock and poultry | |
| CN103989725A (en) | Acalypha australis L. and amikacin containing compound medicine for livestock and poultry | |
| CN103948691B (en) | A kind of poultry compound medicine containing Radix Paeoniae Rubra and sulfamonomethoxine sodium | |
| CN103933086A (en) | Creat/amikacin-containing compound medicine for livestock and fowl | |
| CN103948692B (en) | A kind of livestock and poultry compound medicine containing the radix paeoniae rubrathe and amikacin | |
| CN103989729A (en) | Acalypha australis L. and sulfamonomethoxine sodium containing compound medicine for livestock and poultry | |
| CN103989731A (en) | Acalypha australis L. and florfenicol containing compound medicine for livestock and poultry | |
| CN103989727A (en) | Acalypha australis L. and mequindox containing compound medicine for livestock and poultry | |
| CN103977088B (en) | A kind of poultry compound medicine containing Radix Paeoniae Rubra and fluoroquinolone antibacterial agent | |
| CN104306420A (en) | Balsamiferou blumea herb and sulfamonomethoxine sodium containing compound medicine for livestock and poultry | |
| CN103948656B (en) | A kind of poultry compound medicine containing Herba Andrographis and fosfomycin | |
| CN103989726A (en) | Acalypha australis L. and fosfomycin containing compound medicine for livestock and poultry | |
| CN103127508A (en) | Herba lycopi containing compound composition for treating escherichia coli infected diseases of livestock and poultry | |
| CN104337847B (en) | A kind of livestock and poultry compound medicine containing phoenix-tail fern and phosphonomycin | |
| CN103908670B (en) | A kind of compound treating poultry coli-infection disease | |
| CN104435012A (en) | Pteris multifida and florfenicol-containing compound drug for livestock and poultry | |
| CN104367601A (en) | Compound medicine containing herba pteridis multifidae and mequindox for livestock and poultry | |
| CN103933543A (en) | Method for treating Escherichia coli infection diseases by using creat and colimycin | |
| CN104306422A (en) | Balsamiferou Blumea herb and beta-lactam antibacterial drug containing compound medicine for livestock and poultry | |
| CN104435038A (en) | Balsamiferou blumea herb and mequindox containing compound medicine for livestock and poultry |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180102 Address after: 530100 the Guangxi Zhuang Autonomous Region Nanning Yilin Industrial Zone No. B-9 (Wuming) Patentee after: GUANGXI NANNING TAOYUAN VETERINARY DRUG FACTORY Address before: 530004 the Guangxi Zhuang Autonomous Region XiXiangTang Nanning University Road No. 100 Patentee before: Guangxi University |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160831 |